Introduction of CEMAFLD
中文簡介：
非酒精性脂肪肝病(Non-Alcoholic Fatty Liver Disease, NAFLD)或代謝異常相關脂肪肝病(Metabolic dysfunction-associated Fatty Liver Disease, MAFLD)是全世界最常見的慢性肝病，估計全球約1/4人口有脂肪肝，且逐年上升中，在BC型肝炎逐步被控制及清除之下，MAFLD已成為影響全球人類健康與經濟最重要的疾病之一，然而其致病機轉複雜、防治機制未明、且至今仍缺乏有效治療藥物。為因應MAFLD對國人及全球的健康威脅，本校特設立「代謝異常脂肪肝卓越研究中心」，配合國家發展政策，帶動台灣精準健康產業之開發及衛福部肝炎及肝癌防治計畫，結合國內外專家，進行流病及基礎研究，智慧生醫、醫藥與醫材開發，透過跨領域、跨國多中心臨床研究，制定臨床共識、教育訓練與民眾衛教準則等方法，期以協助代謝異常脂肪肝患者之預防、診斷及治療、改善生活型態、維持健康體位、了解健康管理監測指標，降低患者肝硬化、肝癌及肝外併發症發生之風險，並教育宣導疾病之防治。本中心將與國內外各大學及醫學中心等各領域專家進行合作，設置流行病學組、基礎研究組、全國世代臨床研究組、藥物開發組、智慧醫療器材開發組、及跨領域合作及教育組，進行跨域整合研究，期將研究成果帶入公共衛生政策參考、培育優秀科學研究人才、提供國際互訪交流與學術合作機會，與產業進行產學合作開發，成為亞太第一及全球領先之MAFLD卓越研究中心，推動聯合國永續發展目標。
Introduction of CEMAFLD
Non-Alcoholic Fatty Liver Disease (NAFLD), or named as Metabolic associated fatty liver disease (MAFLD), is the most common chronic liver disease globally, with a prevalence rate of 25%. With the advance in the disease control of HBV and HCV by mass HBV vaccination and antivirals, MAFLD has become the major cause of end-stage liver disease, hepatocellular carcinoma (HCC), and liver transplantation in Europe and USA, which will lead to global health threat with significant economic impact. However, there remain many huge unmet needs in the control of MAFLD, including the pathogenetic mechanisms, prevention, treatment and therapeutic targets. To resolve the threats of MAFLD, we establish “The Center of Excellence for Metabolic Associated Fatty Liver Disease(CEMAFLD)” to conduct a comprehensive investigation on MAFLD, including epidemiology, pathogenesis, diagnosis, management, as well as the development of therapeutic agents and medical devices.
We expect to accomplish international and nationwide epidemiological investigation, establish platforms for clinical cohorts, pathological reading, animal models and education, complete pre-clinical trials of potential pharmaceutical targets, publish MAFLD position statement and consensus guidelines, and conduct professional training programs and public health education. We expect the achievement could be served as reference of policy-making for public health. CEMAFLD also responds to cultivating outstanding scientific research talents, providing opportunities for international exchange visits and academic cooperation, and conducting industry-university cooperative development with industries. The CEMAFLD will become the first and leading global MAFLD Center in Asia-Pacific, and continuously reach Sustainable Development Goals.
非酒精性脂肪肝病(Non-Alcoholic Fatty Liver Disease, NAFLD)或代謝異常相關脂肪肝病(Metabolic dysfunction-associated Fatty Liver Disease, MAFLD)是全世界最常見的慢性肝病，估計全球約1/4人口有脂肪肝，且逐年上升中，在BC型肝炎逐步被控制及清除之下，MAFLD已成為影響全球人類健康與經濟最重要的疾病之一，然而其致病機轉複雜、防治機制未明、且至今仍缺乏有效治療藥物。為因應MAFLD對國人及全球的健康威脅，本校特設立「代謝異常脂肪肝卓越研究中心」，配合國家發展政策，帶動台灣精準健康產業之開發及衛福部肝炎及肝癌防治計畫，結合國內外專家，進行流病及基礎研究，智慧生醫、醫藥與醫材開發，透過跨領域、跨國多中心臨床研究，制定臨床共識、教育訓練與民眾衛教準則等方法，期以協助代謝異常脂肪肝患者之預防、診斷及治療、改善生活型態、維持健康體位、了解健康管理監測指標，降低患者肝硬化、肝癌及肝外併發症發生之風險，並教育宣導疾病之防治。本中心將與國內外各大學及醫學中心等各領域專家進行合作，設置流行病學組、基礎研究組、全國世代臨床研究組、藥物開發組、智慧醫療器材開發組、及跨領域合作及教育組，進行跨域整合研究，期將研究成果帶入公共衛生政策參考、培育優秀科學研究人才、提供國際互訪交流與學術合作機會，與產業進行產學合作開發，成為亞太第一及全球領先之MAFLD卓越研究中心，推動聯合國永續發展目標。
Introduction of CEMAFLD
Non-Alcoholic Fatty Liver Disease (NAFLD), or named as Metabolic associated fatty liver disease (MAFLD), is the most common chronic liver disease globally, with a prevalence rate of 25%. With the advance in the disease control of HBV and HCV by mass HBV vaccination and antivirals, MAFLD has become the major cause of end-stage liver disease, hepatocellular carcinoma (HCC), and liver transplantation in Europe and USA, which will lead to global health threat with significant economic impact. However, there remain many huge unmet needs in the control of MAFLD, including the pathogenetic mechanisms, prevention, treatment and therapeutic targets. To resolve the threats of MAFLD, we establish “The Center of Excellence for Metabolic Associated Fatty Liver Disease(CEMAFLD)” to conduct a comprehensive investigation on MAFLD, including epidemiology, pathogenesis, diagnosis, management, as well as the development of therapeutic agents and medical devices.
We expect to accomplish international and nationwide epidemiological investigation, establish platforms for clinical cohorts, pathological reading, animal models and education, complete pre-clinical trials of potential pharmaceutical targets, publish MAFLD position statement and consensus guidelines, and conduct professional training programs and public health education. We expect the achievement could be served as reference of policy-making for public health. CEMAFLD also responds to cultivating outstanding scientific research talents, providing opportunities for international exchange visits and academic cooperation, and conducting industry-university cooperative development with industries. The CEMAFLD will become the first and leading global MAFLD Center in Asia-Pacific, and continuously reach Sustainable Development Goals.
Click Num:
Share
